TD
MCID: TRD006
MIFTS: 49

Tardive Dyskinesia (TD) malady

Categories: Rare diseases, Neuronal diseases, Oral diseases

Aliases & Classifications for Tardive Dyskinesia

Aliases & Descriptions for Tardive Dyskinesia:

Name: Tardive Dyskinesia 50 51 29 69
Neuroleptic-Induced Tardive Dyskinesia 69
Lingual-Facial-Buccal Dyskinesia 69
Drug-Induced Tardive Dyskinesia 69
Linguofacial Dyskinesia 50
Tardive Oral Dyskinesia 50
Tardive Dystonia 50
Td 50

Characteristics:

HPO:

32
tardive dyskinesia:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Tardive Dyskinesia

NIH Rare Diseases : 50 tardive dyskinesia is a neurological movement disorder that is caused by the long-term use of a certain type of medications called neuroleptics. neuroleptic drugs are usually prescribed for psychiatric conditions, although they may be used to treat gastrointestinal or neurological conditions in some cases. tardive dyskinesia is primarily characterized by repetitive involuntary movements of the jaw, lips and tongue such as grimacing; sticking out the tongue; and smacking, puckering and pursing the lips. some affected people may also experience involuntary rapid, jerking movements (chorea) or slow, writhing movements (athetosis) of the arms and/or legs. it is unclear why some people who take neuroleptic medications develop these symptoms while others do not. treatment for this condition varies but may include stopping or minimizing the use of neuroleptic drugs and/or taking additional medications to to reduce the severity of the symptoms. last updated: 12/18/2014

MalaCards based summary : Tardive Dyskinesia, also known as neuroleptic-induced tardive dyskinesia, is related to schizophrenia and drug induced dyskinesia, and has symptoms including abnormality of the nervous system, spasmodic torticollis and myoclonus. An important gene associated with Tardive Dyskinesia is NQO1 (NAD(P)H Quinone Dehydrogenase 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and Monoamine GPCRs. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include tongue, eye and brain, and related phenotypes are behavior/neurological and digestive/alimentary

NINDS : 51 Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Involuntary movements of the fingers may be present.

Wikipedia : 71 Tardive dyskinesia (TD) is a difficult-to-treat and often incurable form of dyskinesia, a disorder... more...

Related Diseases for Tardive Dyskinesia

Diseases related to Tardive Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
id Related Disease Score Top Affiliating Genes
1 schizophrenia 30.2 BDNF CYP1A2 CYP2D6 DRD2 DRD3 HTR2A
2 drug induced dyskinesia 11.4
3 dystonia 10.4
4 sphenoorbital meningioma 10.2 DRD2 DRD3
5 intracranial aneurysm 10.2 DRD2 DRD3
6 c8 deficiency, type ii 10.2 DRD2 DRD3
7 splenic abscess 10.1 DRD2 HTR2A
8 euthyroid sick syndrome 10.1 DRD2 HTR2A
9 waardenburg's syndrome 10.1 DRD2 HTR2A
10 mood disorder 10.1
11 neuronitis 10.1
12 chorea gravidarum 10.0 CYP2D6 DRD2
13 pyromania 10.0 DRD2 DRD3 HTR2A
14 allergic hypersensitivity disease 10.0 DRD2 HTR2A
15 cecal benign neoplasm 10.0 DRD2 DRD3 HTR2A
16 hypoglycemia 10.0 BDNF DRD2 DRD3
17 alopecia 10.0 BDNF DRD2 DRD3
18 vascular cancer 10.0 DRD2 HTR2A
19 intrahepatic gall duct cancer 10.0 BDNF HTR2A
20 microcephaly 13, primary, autosomal recessive 10.0 DRD2 DRD3 HTR2A
21 ischemic neuropathy 10.0 CYP2D6 DRD2 DRD3
22 dementia 10.0
23 hypothyroidism 10.0
24 bipolar disorder 10.0
25 intellectual disability 10.0
26 urea cycle disorder 10.0 BDNF DRD2
27 multiple personality disorder 10.0 BDNF HTR2A
28 postencephalitic parkinson disease 9.9 BDNF DRD2 HTR2A
29 hereditary multiple exostoses 9.9 BDNF DRD2 HTR2A
30 trichomegaly 9.9 CYP1A2 CYP2D6
31 benign epilepsy with centrotemporal spikes 9.9 BDNF DRD2 HTR2A
32 gas gangrene 9.9 CYP1A2 CYP2D6
33 keratosis 9.9 BDNF CYP2D6 HTR2A
34 tinea pedis 9.9 CYP1A2 CYP2D6
35 hypoglycemic coma 9.8 BDNF HTR2A
36 cytomegalic congenital adrenal hypoplasia 9.8 BDNF DRD2 DRD3 HTR2A
37 epithelioid type angiomyolipoma 9.8 BDNF CYP2D6 HTR2A
38 brain glioblastoma multiforme 9.8 BDNF DRD2 DRD3 HTR2A
39 tremor 9.8
40 bipolar i disorder 9.8
41 endotheliitis 9.8
42 cervicitis 9.8
43 bursitis 9.8
44 huntington disease 9.8
45 myelitis 9.8
46 choreoacanthocytosis 9.8
47 gilles de la tourette syndrome 9.8
48 cerebritis 9.8
49 blepharospasm 9.8
50 cataract 9.8

Comorbidity relations with Tardive Dyskinesia via Phenotypic Disease Network (PDN): (show all 15)


Acute Cystitis Alzheimer Disease
Anxiety Disorder Bipolar Disorder
Decubitus Ulcer Deficiency Anemia
Dysthymic Disorder Esophagitis
Hypertension, Essential Hypothyroidism
Paranoid Schizophrenia Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Schizophrenia
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Tardive Dyskinesia:



Diseases related to Tardive Dyskinesia

Symptoms & Phenotypes for Tardive Dyskinesia

Human phenotypes related to Tardive Dyskinesia:

32
id Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 32 HP:0000707
2 tardive dyskinesia 32 HP:0040141

UMLS symptoms related to Tardive Dyskinesia:


spasmodic torticollis, myoclonus

MGI Mouse Phenotypes related to Tardive Dyskinesia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 DRD3 HSPG2 HTR2A SOD2 BDNF CYP1A2
2 digestive/alimentary MP:0005381 9.35 DRD2 DRD3 HSPG2 HTR2A BDNF
3 liver/biliary system MP:0005370 9.02 HSPG2 NQO1 SOD2 CYP1A2 DRD2

Drugs & Therapeutics for Tardive Dyskinesia

Drugs for Tardive Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 1 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1 106266-06-2 5073
3 Zotepine Approved Phase 4 26615-21-4
4
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
5
Zolpidem Approved Phase 4 82626-48-0 5732
6
Nicotine Approved Phase 4 54-11-5 942 89594
7
Galantamine Approved Phase 4 357-70-0 9651 908828, 9651
8
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1 132539-06-1 4585
9
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
10
Ziprasidone Approved Phase 4 146939-27-7 60854
11
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
12
Chlorpromazine Approved, Vet_approved Phase 4 50-53-3 2726
13 tannic acid Approved, Nutraceutical Phase 4
14
Serotonin Phase 4,Phase 3,Phase 1 50-67-9 5202
15 Serotonin Agents Phase 4,Phase 3,Phase 1
16 Serotonin Antagonists Phase 4,Phase 3,Phase 1
17 GABA Agents Phase 4
18 GABA Agonists Phase 4
19 GABA-A Receptor Agonists Phase 4
20 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
21 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Dopamine Agents Phase 4,Phase 3,Phase 1
23 Dopamine Antagonists Phase 4,Phase 3,Phase 1
24 Hypnotics and Sedatives Phase 4
25 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
26 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
28 sultopride Phase 4
29 Cholinergic Agents Phase 4,Phase 1,Phase 2
30 Cholinesterase Inhibitors Phase 4
31 Serotonin Uptake Inhibitors Phase 4,Phase 1
32 Gastrointestinal Agents Phase 4,Phase 1
33 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 1
34 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
35 Cytochrome P-450 Enzyme Inhibitors Phase 4
36 Nootropic Agents Phase 4,Phase 3,Phase 2
37 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
38 Dopamine Uptake Inhibitors Phase 4
39 Antidepressive Agents Phase 4
40 Antidepressive Agents, Second-Generation Phase 4
41 Antiemetics Phase 4,Phase 1
42 Autonomic Agents Phase 4,Phase 1
43 Lithium carbonate Phase 4 554-13-2
44 Antimanic Agents Phase 4
45 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 2
46 Piracetam Approved Phase 3,Phase 2 7491-74-9
47
Tetrabenazine Approved Phase 3 58-46-8 6018
48
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 65-23-6 1054
49
Pyridoxal Approved, Nutraceutical Phase 3,Phase 2 66-72-8 1050
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037

Interventional clinical trials:

(show all 50)
id Name Status NCT ID Phase
1 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4
2 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4
3 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4
4 Treatment of Tardive Dyskinesia With Galantamine Completed NCT00164242 Phase 4
5 Tardive Dyskinesia and Cognitive Function Completed NCT00926965 Phase 4
6 Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia Completed NCT00621998 Phase 4
7 Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia Completed NCT00114595 Phase 4
8 The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia Completed NCT00495352 Phase 4
9 Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics Completed NCT00458211 Phase 4
10 Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features Recruiting NCT00202293 Phase 4
11 A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02274558 Phase 3
12 Piracetam for Treatment Tardive Dyskinesia Completed NCT00190008 Phase 3
13 Extract of Ginkgo Biloba and Tardive Dyskinesia Completed NCT00672373 Phase 3
14 Addressing Involuntary Movements in Tardive Dyskinesia Completed NCT02291861 Phase 3
15 Aim to Reduce Movements in Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3
16 Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02405091 Phase 3
17 Levetiracetam Treatment of Tardive Dyskinesia Completed NCT00291213 Phase 3
18 A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia Completed NCT00210769 Phase 3
19 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3
20 Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation Completed NCT00065286 Phase 3
21 Xenazine in Late Dyskinetic Syndrome With Neuroleptics Recruiting NCT01543321 Phase 3
22 Reducing Involuntary Movements in Tardive Dyskinesia Active, not recruiting NCT02198794 Phase 3
23 D-Serine Treatment For Tardive Dyskinesia Active, not recruiting NCT01804920 Phase 2, Phase 3
24 Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Enrolling by invitation NCT02736955 Phase 3
25 A Phase 2/3 Study of MT-5199 for the Treatment in Patients With Tardive Dyskinesia Not yet recruiting NCT03176771 Phase 2, Phase 3
26 Pyridoxal Kinase Activity in Tardive Dyskinesia Withdrawn NCT01908452 Phase 3
27 Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia Unknown status NCT00621634 Phase 2
28 Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia Unknown status NCT00331669 Phase 2
29 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT01393600 Phase 2
30 Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia Completed NCT01267188 Phase 2
31 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) Completed NCT01688037 Phase 2
32 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia Completed NCT01733121 Phase 2
33 A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia Completed NCT02064010 Phase 2
34 Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia Completed NCT00175955 Phase 2
35 Heart Rate Variability in Response to Metformin Challenge Completed NCT02500628 Phase 2
36 Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia Completed NCT00401089 Phase 1, Phase 2
37 Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia Completed NCT01176721 Phase 2
38 Dysport for the Treatment of OMD Active, not recruiting NCT01921270 Phase 1, Phase 2
39 Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia Terminated NCT00917293 Phase 2
40 Movement Disorders Caused by Antipsychotic Drugs in Older Patients Completed NCT00255879 Phase 1
41 Melatonin Treatment for Tardive Dyskinesia in Schizophrenia Completed NCT01391390
42 The Assessment of Movement Disorders Utilizing Live Two-Way Video Completed NCT01467089
43 CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness Completed NCT01149551
44 Effect of Activity on Sleep of Cognitively-Impaired Veterans Completed NCT00013182
45 Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents Recruiting NCT03062033
46 Validation of the Implantation of a New Electrode for the Treatment of Dystonia Recruiting NCT02509338
47 ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders Recruiting NCT02252380
48 Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia. Not yet recruiting NCT02840760
49 Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia Terminated NCT00310661
50 Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia Terminated NCT02524886

Search NIH Clinical Center for Tardive Dyskinesia

Genetic Tests for Tardive Dyskinesia

Genetic tests related to Tardive Dyskinesia:

id Genetic test Affiliating Genes
1 Tardive Dyskinesia 29

Anatomical Context for Tardive Dyskinesia

MalaCards organs/tissues related to Tardive Dyskinesia:

39
Tongue, Eye, Brain, Globus Pallidus, Testes, Cortex, Endothelial

Publications for Tardive Dyskinesia

Articles related to Tardive Dyskinesia:

(show top 50) (show all 602)
id Title Authors Year
1
Clozapine Treatment of Olanzapine-induced Tardive Dyskinesia: A Case Report. ( 28072646 )
2017
2
Propranolol therapy for Tardive dyskinesia: A retrospective examination. ( 27622970 )
2016
3
Tardive Dyskinesia, Oral Parafunction, and Implant-Supported Rehabilitation. ( 28050290 )
2016
4
Two Cases of Iloperidone-Related Tardive Dyskinesia. ( 27749678 )
2016
5
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data. ( 27138080 )
2016
6
Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. ( 28044943 )
2016
7
Markedly Reduced Thermal Pain Perception in a Schizoaffective Patient with Tardive Dyskinesia. ( 27144045 )
2016
8
Association between DBH 19bp insertion/deletion polymorphism and cognition in schizophrenia with and without tardive dyskinesia. ( 27776953 )
2016
9
A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution. ( 27818825 )
2016
10
Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. ( 26791148 )
2016
11
Report: Protective effects of rice bran oil in haloperidol-induced tardive dyskinesia and serotonergic responses in rats. ( 27592482 )
2016
12
Successful Management of Tardive Dyskinesia with Quetiapine and Clonazepam in a Patient of Schizophrenia with Type 2 Diabetes Mellitus. ( 27121435 )
2016
13
Laughter therapy in a geriatric patient with treatment-resistant depression and comorbid tardive dyskinesia. ( 27164922 )
2016
14
Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. ( 27127627 )
2016
15
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data. ( 27123800 )
2016
16
Co-morbid obsessive compulsive and hypochondriac disorders complicated by tardive dyskinesia in a Nigerian man. ( 26755234 )
2016
17
Association study of MiRSNPs with schizophrenia, tardive dyskinesia and cognition. ( 27106592 )
2016
18
Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia. ( 27565433 )
2016
19
Pharmacogenetics of tardive dyskinesia: an updated review of the literature. ( 27469238 )
2016
20
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. ( 27091214 )
2016
21
Paliperidone Palmitate-Associated Severe Refractory Tardive Dyskinesia With Tardive Dystonia: Management and Six-Months Follow-Up. ( 27269958 )
2016
22
Divalproex sodium leading to sustained significant improvement in tardive dyskinesia in a patient with bipolar disorder. ( 26985118 )
2016
23
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept Studies. ( 26813487 )
2016
24
Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model. ( 27264436 )
2016
25
Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia. ( 27658674 )
2016
26
Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of Randomized Controlled Trials. ( 26979525 )
2016
27
High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature. ( 27141296 )
2016
28
Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug. ( 26492119 )
2015
29
Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia. ( 25600548 )
2015
30
Utilizing the concept of geste antagoniste for conservative management of oro-mandibular tardive dyskinesia: a case report and mini-review. ( 26293144 )
2015
31
Tardive dyskinesia and covert dyskinesia with Aripiprazole: a case series. ( 26391425 )
2015
32
Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. ( 25866243 )
2015
33
Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. ( 25602162 )
2015
34
Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. ( 26679687 )
2015
35
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1. ( 26348804 )
2015
36
Valbenazine granted breakthrough drug status for treating tardive dyskinesia. ( 25809133 )
2015
37
Identification and management of tardive dyskinesia: A case series and literature review. ( 26216578 )
2015
38
Mn-superoxide dismutase activity is associated with orofacial involuntary movements in schizophrenia patients with tardive dyskinesia. ( 25572310 )
2015
39
Lifelong Rodent Model of Tardive Dyskinesia-Persistence After Antipsychotic Drug Withdrawal. ( 26472552 )
2015
40
The association between COMT Val158Met gene polymorphism and antipsychotic-induced tardive dyskinesia risk. ( 26398367 )
2015
41
Efficacy of aripiprazole in antidepressants-induced tardive dystonia and tardive dyskinesia: a case report. ( 26057318 )
2015
42
Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials. ( 26166007 )
2015
43
Erratum for Vinuela A, Kang UJ. Reversibility of tardive dyskinesia syndrome. Tremor Other Hyperkinet Mov. 2014; 4. doi: 10.7916/D86Q1VXZ. ( 26417537 )
2015
44
A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia. ( 25679121 )
2015
45
NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. ( 26346941 )
2015
46
A case of tardive dyskinesia in the last weeks of life. ( 26095485 )
2015
47
Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study. ( 25485636 )
2015
48
Late-onset Quetiapine-related Tardive Dyskinesia Side Effects in a Patient with Psychotic Depression. ( 25191509 )
2014
49
Reversibility of tardive dyskinesia syndrome. ( 25493205 )
2014
50
BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: A meta-analysis. ( 24411528 )
2014

Variations for Tardive Dyskinesia

Expression for Tardive Dyskinesia

Search GEO for disease gene expression data for Tardive Dyskinesia.

Pathways for Tardive Dyskinesia

Pathways related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 11)
id Super pathways Score Top Affiliating Genes
1 11.72 CYP1A2 CYP2D6 NQO1 SOD2
2
Show member pathways
11.49 DRD2 DRD3 HTR2A
3
Show member pathways
11.23 CYP1A2 CYP2D6 NQO1
4 11.18 CYP1A2 NQO1
5 11.16 CYP1A2 NQO1
6
Show member pathways
11.14 CYP1A2 CYP2D6
7 11 CYP1A2 CYP2D6
8
Show member pathways
10.94 CYP1A2 NQO1
9 10.86 NQO1 SOD2
10 10.72 DRD2 DRD3
11
Show member pathways
10.55 CYP1A2 CYP2D6 NQO1

GO Terms for Tardive Dyskinesia

Biological processes related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 45)
id Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.99 CYP1A2 CYP2D6 NQO1 SOD2
2 aging GO:0007568 9.83 HTR2A NQO1 SOD2
3 response to ethanol GO:0045471 9.79 DRD2 DRD3 NQO1
4 locomotory behavior GO:0007626 9.72 DRD2 DRD3 SOD2
5 xenobiotic metabolic process GO:0006805 9.71 CYP1A2 CYP2D6 NQO1
6 visual learning GO:0008542 9.7 DRD2 DRD3
7 response to cocaine GO:0042220 9.69 DRD2 DRD3
8 release of sequestered calcium ion into cytosol GO:0051209 9.69 DRD2 HTR2A
9 negative regulation of protein kinase B signaling GO:0051898 9.68 DRD2 DRD3
10 positive regulation of cytokinesis GO:0032467 9.68 DRD2 DRD3
11 negative regulation of blood pressure GO:0045776 9.68 DRD2 DRD3
12 response to morphine GO:0043278 9.68 DRD2 DRD3
13 response to axon injury GO:0048678 9.67 DRD2 SOD2
14 negative regulation of adenylate cyclase activity GO:0007194 9.67 DRD2 DRD3
15 response to amphetamine GO:0001975 9.67 DRD2 DRD3
16 arachidonic acid secretion GO:0050482 9.66 DRD2 DRD3
17 response to immobilization stress GO:0035902 9.65 CYP1A2 SOD2
18 drug metabolic process GO:0017144 9.65 CYP1A2 CYP2D6
19 superoxide metabolic process GO:0006801 9.65 NQO1 SOD2
20 temperature homeostasis GO:0001659 9.64 DRD2 HTR2A
21 dopamine receptor signaling pathway GO:0007212 9.64 DRD2 DRD3
22 synaptic transmission, dopaminergic GO:0001963 9.63 DRD2 DRD3
23 removal of superoxide radicals GO:0019430 9.63 NQO1 SOD2
24 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.62 DRD2 HTR2A
25 dopamine metabolic process GO:0042417 9.62 DRD2 DRD3
26 prepulse inhibition GO:0060134 9.61 DRD2 DRD3
27 positive regulation of renal sodium excretion GO:0035815 9.6 DRD2 DRD3
28 negative regulation of protein secretion GO:0050709 9.59 DRD2 DRD3
29 G-protein coupled receptor internalization GO:0002031 9.58 DRD2 DRD3
30 hydrogen peroxide biosynthetic process GO:0050665 9.58 CYP1A2 SOD2
31 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.57 DRD2 DRD3
32 oxidative demethylation GO:0070989 9.56 CYP1A2 CYP2D6
33 response to drug GO:0042493 9.55 CYP1A2 DRD2 DRD3 HTR2A SOD2
34 regulation of cAMP metabolic process GO:0030814 9.52 DRD2 DRD3
35 drug catabolic process GO:0042737 9.51 CYP1A2 CYP2D6
36 heterocycle metabolic process GO:0046483 9.49 CYP1A2 CYP2D6
37 monoterpenoid metabolic process GO:0016098 9.48 CYP1A2 CYP2D6
38 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.46 DRD2 DRD3
39 negative regulation of dopamine receptor signaling pathway GO:0060160 9.43 DRD2 DRD3
40 acid secretion GO:0046717 9.4 DRD2 DRD3
41 response to histamine GO:0034776 9.37 DRD2 DRD3
42 alkaloid metabolic process GO:0009820 9.32 CYP1A2 CYP2D6
43 regulation of locomotion involved in locomotory behavior GO:0090325 9.26 DRD2 DRD3
44 regulation of dopamine secretion GO:0014059 9.13 DRD2 DRD3 HTR2A
45 behavioral response to cocaine GO:0048148 8.8 DRD2 DRD3 HTR2A

Molecular functions related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.76 CYP1A2 CYP2D6 NQO1 SOD2
2 aromatase activity GO:0070330 9.43 CYP1A2 CYP2D6
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.4 CYP1A2 CYP2D6
4 dopamine binding GO:0035240 9.37 DRD2 DRD3
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.32 DRD2 DRD3
6 superoxide dismutase activity GO:0004784 9.26 NQO1 SOD2
7 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD2 DRD3
8 oxygen binding GO:0019825 9.13 CYP1A2 CYP2D6 SOD2
9 drug binding GO:0008144 8.92 CYP2D6 DRD2 DRD3 HTR2A

Sources for Tardive Dyskinesia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....